Navigation Links
Lorus Therapeutics Provides an Update on Progress in Virulizin(R) Development Program
Date:7/9/2008

ed for the treatment of a serious or life-threatening condition and that it has the potential to address unmet medical needs for the condition. Virulizin(R) is a registered trademark owned by Lorus Therapeutics Inc.

About Lorus

Lorus is a biopharmaceutical company focused on the research and development of novel therapeutics in cancer. Lorus' goal is to capitalize on its research, preclinical, clinical and regulatory expertise by developing new drug candidates that can be used, either alone, or in combination with other drugs, to successfully manage cancer. Through its own discovery efforts and an acquisition and in-licensing program, Lorus is building a portfolio of promising anticancer drugs. Lorus Therapeutics Inc. is listed on the Toronto Stock Exchange under the symbol LOR, and on the American Stock Exchange under the symbol LRP.

Forward-Looking Statements

This press release may contain forward-looking statements within the meaning of Canadian and U.S. securities laws. Such statements include, but are not limited to, statements relating to: our research program plans, our plans to conduct clinical trials, the successful and timely completion of clinical studies and the regulatory approval process, our ability to fund future research, our plans to obtain partners to assist in the further development of our product candidates, the establishment of corporate alliances, the Company's plans, objectives, expectations and intentions and other statements including words such as "continue", "believe", "plan", "expect", "intend", "will", "should", "may", and other similar expressions. Such statements reflect our current views with respect to future events and are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by us are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies. Many factors cou
'/>"/>

SOURCE Lorus Therapeutics Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related biology technology :

1. Lorus Advances Clinical Development of GTI-2040 Combined with Ara-C in Acute Myeloid Leukemia
2. Lorus Therapeutics Appoints Peter Korth as Chief Financial Officer
3. Lorus Therapeutics Announces Exclusive Multinational License Agreement with Zoticon Bioventures for Virulizin(R)
4. Lorus Therapeutics presents new findings for the anticancer drugs LOR-253 and LOR-2040
5. Lorus initiates development program exploring novel route of administration for LOR-2040
6. Lorus Therapeutics Strengthens Its Senior Management Team Through Internal Promotions
7. Lorus Therapeutics Announces Publication of a Clinical Study Demonstrating Encouraging Results with LOR-2040 in Combination with Cytarabine in Patients with Acute Myeloid Leukemia (AML)
8. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
9. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
10. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
11. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... Earth, MN (PRWEB) June 19, 2013 ... of abuse tests, today announced that it has received ... to market and sell its DrugCheck® NxStep Onsite ... allows use of the rapid screening device in near-patient ... Onsite Drug Screen Cup received Health Canada Class III ...
(Date:6/18/2013)... HONG KONG, June 18, 2013 China Cord ... the "Company"), China,s leading provider of cord blood collection, ... storage services, today announced its preliminary unaudited financial results ... year 2013 ended March 31, 2013. ... for the fourth quarter of fiscal 2013 increased by ...
(Date:6/18/2013)... 18, 2013 Demanding industrial and environmental ... of synthetic Sapphire and Glass Ball Lenses, now available ... Swiss Jewel Company , of Philadelphia , PA. , ... collimating the light beams without the need for direct ... natural durability (9 mohs) make it the ideal choice ...
(Date:6/18/2013)... JERUSALEM , June 18, 2013 ... study using the company,s  proprietary AMCA Guided Bone Regeneration (GBR) ... dental implants. A common problem encountered when patients ... lack of sufficient bone volume to house the implant. Consequently ... a bone substitute until the natural bone regenerates. The bone ...
Breaking Biology Technology:Express Diagnostics’ DrugCheck® On-site Test Cup Receives Health Canada Class III Medical Device Approval 2Express Diagnostics’ DrugCheck® On-site Test Cup Receives Health Canada Class III Medical Device Approval 3China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 2China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 3China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 4China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 5China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 6China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 7China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 8China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 9China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 10China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 11China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 12China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 13Swiss Jewel Introduces the Crown Jewels of Fiber-Optic Connectors 2RegeneCure Starts Clinical Study Using Polymeric Bone Stimulating Membrane for Dental Implants 2RegeneCure Starts Clinical Study Using Polymeric Bone Stimulating Membrane for Dental Implants 3
... System and GE Medical Systems recently signed a five-year ... medical field. The Wheaton Franciscan System, a Catholic heath ... GE Medical System s Performance Solutions; a portfolio ... care customers in addition to the purchase of imaging ...
... Wis. -- Bruker AXS Inc., a provider of X-ray ... that it has been selected to participate in the ... The project is half-funded by the Dutch government, and ... expects to receive approximately $950,000 in matching funds. ...
... , a provider of integrated data solutions for ... Friday. The service allows customers to meet with ... and other online collaborations. , ,Norlight's Guardian ... visual benefits of Web collaboration. Using a Web-based ...
Cached Biology Technology:
(Date:6/17/2013)... may help delay early onset of puberty in girls, ... Monday at The Endocrine Society,s 95th Annual Meeting in ... the ages of 10 and 14. Boys undergo these ... age. Precocious puberty is diagnosed in girls when sexual ... it is diagnosed when these changes occur before age ...
(Date:6/17/2013)... be the topics under discussion during the E3 ... third consecutive year, this will be a unique ... among members of Academy, Business, Educators, Entrepreneurs, Innovators, ... Elisa Martn Garijo (IBM South Europe), Chris Zegras ... O,Donovan (Hovione), among others. E3 Forum - Education, ...
(Date:6/16/2013)... for female sex workers in India reduce rates of ... University of Toronto study has found. , ... in the southern states of Andhra Pradesh, Karnataka, Maharashtra ... Jha from U of T,s Dalla Lana School of ... Health Research (CGHR), examined the impact of prevention among ...
Breaking Biology News(10 mins):Vitamin D supplementation may delay precocious puberty in girls 2'E3 Forum -- Education, Employment & Entrepreneurship on a Global context' 2HIV prevention among female sex workers in India reduces HIV and syphilis 2
... Thomas C. Quinn, M.D., a Johns Hopkins physician and scientist, ... years leading major efforts to combat HIV and AIDS throughout ... confront the rapid "feminization" of the AIDS pandemic. , Quinn, ... investigator at the National Institute of Allergy and Infectious Disease, ...
... people, naturally produce disease-fighting chemicals, called antimicrobial peptides, ... some disease-causing bacteria have evolved antimicrobial detectors. The ... a warning signal. This alarm sets off a ... University of Washington (UW) and McGill University researchers ...
... of the three-dimensional terrain of a synapse -- the ... the brain and nervous system. The "nano-map," which shows ... or one-billionth of a meter, has already proven its ... , Using the map as a guide, the research ...
Cached Biology News:AIDS expert says global strategy needed to combat feminization of HIV/AIDS 2AIDS expert says global strategy needed to combat feminization of HIV/AIDS 3Bacteria recognize antimicrobials, respond with counter-defenses 2The synapse is a shotgun 2The synapse is a shotgun 3
...
... potent inhibition of RNase A-type ribonucleases Product ... of nonhuman origin that binds noncovalently and ... A, B, and C). It does not ... U2, or CL3. QIAGEN RNase Inhibitor inhibits ...
...
... Radiochemical Purity is >95%\nNEN Radiolabeled Ligands\n\nReceptor-related ... continual availability of new radiolabeled ligands selected ... offers a wide range of products and ... including over 400 state-of-the-art radioligands. If you ...
Biology Products: